ASX:ATXPharmaceuticals, Biotechnology & Life SciencesBiotechnology
Amplia Therapeutics Ltd
$0.150
Day Range
$0.148 – $0.150
52 Week Range
$0.100 – $0.275
Volume
0.00
Avg Volume (10D)
568.26K
Market Cap
$77.00M
Price Chart
OHLC · volume · moving averages
$0.150+$0.030 (+25.00%)over 6M
Hi$0.275Lo$0.100Avg Vol2.7M
Price-sensitive newsVolumePrev close · 52W rangeDrag the handles below to zoom
Market Statistics
Today's trading range
Open
$0.150
Previous Close
$0.150
Day High
$0.150
Day Low
$0.148
52 Week High
$0.275
52 Week Low
$0.100
Valuation
Fundamental multiples
Market Cap
77.00M
Shares Outstanding
513.31M
Price to Book
1.95
Trading Activity
Volume & order book
Volume
0.00
Value Traded
0.00
Bid
$0.150 × 279,074
Ask
$0.145 × 20,000
Performance
Returns across timeframes
1 Day
0.00%
5 Day
3.45%
13 Week
15.38%
52 Week
-18.92%
YTD
0.00%
Technical Indicators
Momentum & moving averages
RSI (14)
54.45
50-Day SMA
$0.140
200-Day SMA
$0.141
— From the desk
Latest News
Biotechnology
Amplia Therapeutics Partners with Eli Lilly in FAK-KRAS Combination Lung Cancer Trial
Amplia Therapeutics partners with Eli Lilly for a Phase 1b/2b NSCLC trial of narmafotinib plus olomorasib, targeting KRAS G12C resistance and expanding market.
Biotechnology
Amplia Therapeutics Launches New Narmafotinib Ovarian Cancer Study with ANZGOG
Amplia Therapeutics launches PRROSE trial with narmafotinib and ANZGOG in ovarian cancer; 15–20 patients, safety focus, biomarker data.
Biotechnology
Amplia Therapeutics Halts AMPLICITY Trial Recruitment After Chemo-Related DLTs
Amplia Therapeutics halts AMPLICITY recruitment after DLTs with narmafotinib mFOLFIRINOX; pivots to new combos, delaying readouts and raising investor risk.
Biotechnology
Amplia Therapeutics Reports Stronger Efficacy and Survival in Pancreatic Cancer Trial
Amplia Therapeutics reports ACCENT trial: 7.8% CR, 35.9% ORR, 11.1-month median OS in pancreatic cancer; trading halt ahead of AACR.